Skip to main content
. 2017 Feb 2;8(9):15827–15837. doi: 10.18632/oncotarget.15015

Figure 3. Inhibition of PLK1 sensitizes IDH1 mutant cells to TMZ.

Figure 3

A. Western blot using phospho-specific antibodies shows increased PLK1 activation and decreased CHK1 activation in mutant IDH1 astrocytes after TMZ treatment compared to control and WT astrocytes. B. Clonogenic survival of IDH1 mutant astrocytes following treatment with TMZ and a PLK1 inhibitor, BI2536. C. Western blot for total and activate CHK1 in IDH1 mutant astrocytes treated with TMZ and BI2536. Error bars represent SEM. n=3. P<0.001 (***).